# An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

> **NCT05514873** · PHASE3 · COMPLETED · sponsor: **UCB Biopharma SRL** · enrollment: 26 (actual)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** zilucoplan (RA101495)

## Key facts

- **NCT ID:** NCT05514873
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-31
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-10-23
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514873

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514873, "An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05514873. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*